Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1647 1674 1677
This examiner grants 50% of resolved cases
Regina M Deberry works in Art Unit 1647 within Tech Center 1600. She has 603 resolved cases and an allowance rate of 50.1%. This suggests a moderate level of difficulty for applicants.
The median days to allowance is 1238. The interview lift is 30.6%, which is a high value. This indicates that interviews are very effective at increasing the likelihood of an application being allowed.
The 50.1% allowance rate and 1238 days to allowance define the typical prosecution experience. The 30.6% interview lift is a critical strategic tool for practitioners. With 603 resolved cases, these metrics suggest that direct engagement is highly beneficial in Art Unit 1647.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17760984 | CAMPHORSULFONIC ACID AND COMBINATIONS THEREOF WITH CATIONIC EXCIPIENTS AS VISCOSITY REDUCING AGENTS IN HIGH CONCENTRATED PROTEIN FORMULATIONS | Final Rejection | MERCK PATENT GMBH |
| 18413682 | FC Variants and Methods for Their Production | Non-Final OA | Genentech, Inc. |
| 18629145 | METHOD AND DEVICE FOR DETECTING SIGLEC12 | Non-Final OA | The Regents of the University of California |
| 18032080 | FORMULATION FOR WOUND HEALING | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18041123 | METABOLISM-BASED CHIMERIC ANTIGEN RECEPTORS AND METHODS OF TREATMENT | Non-Final OA | Arizona Board of Regents on behalf of Arizona State University |
| 17327504 | METHODS FOR TREATING EOSINOPHILIC ESOPHAGITIS BY ADMINISTERING AN IL-4R INHIBITOR | Final Rejection | SANOFI BIOTECHNOLOGY |
| 17640293 | THERAPEUTIC FUSION PROTEINS | Non-Final OA | NOVARTIS AG |
| 17782469 | STANDARD SUBSTANCE FOR PSA QUANTIFICATION, PREPARATION METHOD THEREFOR, STANDARD SOLUTION FOR PSA QUANTIFICATION, AND PSA QUANTIFICATION METHOD | Non-Final OA | OTSUKA PHARMACEUTICAL CO., LTD. |
| 18477010 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING ALTERNATING ELECTRIC FIELDS AND DENDRITIC CELLS | Non-Final OA | Novocure GmbH |
| 18645245 | Method for purifying PEGylated erythropoietin | Final Rejection | Hoffmann-La Roche Inc. |
| 18301180 | HYALURONIC ACID BINDING DERIVATIVES OF VERSICAN (VG1) FOR LONG ACTING DELIVERY OF THERAPEUTICS | Non-Final OA | HOFFMANN-LA ROCHE INC. |
| 15733387 | MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS IMMUNODIAGNOSTIC ANTIGENS, METHODS, AND KITS COMPRISING SAME | Non-Final OA | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE |
| 18030983 | COMPOSITIONS FOR TREATMENT ALOPECIA AREATA, BIOMARKERS FOR TREATMENT SUCCESS AND, METHODS OF USE THEREOF | Non-Final OA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI |
| 18682310 | METHODS FOR TREATING SICKLE CELL DISEASE OR BETA THALASSEMIA USING A COMPLEMENT ALTERNATIVE PATHWAY INHIBITOR | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 18637050 | ANTIBODY-DRUG CONJUGATE | Final Rejection | GENAHEAD BIO, INC. |
| 16311464 | ANTIBODY-DRUG CONJUGATE | Final Rejection | GENAHEAD BIO, INC. |
| 17279857 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Final Rejection | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT |
| 18030584 | NOVEL PROTEIN SPECIFICALLY BINDING TO CALRETICULIN AND HAVING HUMAN FIBRONECTIN DOMAIN III SCAFFOLD AND USE THEREOF | Non-Final OA | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy